lurtotecan has been researched along with Carcinoma, Epidermoid in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Baron, B; Bloch, J; Borner, M; Chollet, P; Degardin, M; Dittrich, C; Duffaud, F; Fumoleau, P; Lacombe, D; Rolland, F; Vermorken, JB | 1 |
1 trial(s) available for lurtotecan and Carcinoma, Epidermoid
Article | Year |
---|---|
Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis | 2004 |